BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Sensorion has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission. The submission is a preliminary step in the company's evaluation of a potential U.S. initial public offering of its ordinary shares, including in the form of ADSs, and the listing of such ADSs on a U.S. national exchange.
Sensorion is a clinical-stage biotech company, which specializes in the development of therapies to restore, treat, and prevent hearing loss disorders. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases.
For More Such Health News, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
